Tags

Type your tag names separated by a space and hit enter

5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits.
Eur J Pharmacol. 1993 Jul 20; 238(2-3):291-6.EJ

Abstract

The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, MMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, Purdue University, School of Pharmacy and Pharmacal Sciences, West Lafayette, IN 47907.No affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8104811

Citation

Huang, X, and D E. Nichols. "5-HT2 Receptor-mediated Potentiation of Dopamine Synthesis and Central Serotonergic Deficits." European Journal of Pharmacology, vol. 238, no. 2-3, 1993, pp. 291-6.
Huang X, Nichols DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol. 1993;238(2-3):291-6.
Huang, X., & Nichols, D. E. (1993). 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. European Journal of Pharmacology, 238(2-3), 291-6.
Huang X, Nichols DE. 5-HT2 Receptor-mediated Potentiation of Dopamine Synthesis and Central Serotonergic Deficits. Eur J Pharmacol. 1993 Jul 20;238(2-3):291-6. PubMed PMID: 8104811.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. AU - Huang,X, AU - Nichols,D E, PY - 1993/7/20/pubmed PY - 1993/7/20/medline PY - 1993/7/20/entrez SP - 291 EP - 6 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 238 IS - 2-3 N2 - The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, MMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/8104811/5_HT2_receptor_mediated_potentiation_of_dopamine_synthesis_and_central_serotonergic_deficits_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0014-2999(93)90859-G DB - PRIME DP - Unbound Medicine ER -